NTHINeonc Technologies, Inc.Signing up patients
NEO100 and High-Grade Meningioma
Residual, Progressive or Recurrent Grade II or III Meningioma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 30 (planned)
- Started
- Jul 1, 2022
- Main results expected
- Dec 30, 2026
- Fully finished
- Jun 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival as six months (PFS6).
Measured over: 6 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05023018 · record last updated 2026-09-15 · checked 2026-11-09 15:47 UTC